AR068914A1 - Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia - Google Patents
Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejiaInfo
- Publication number
- AR068914A1 AR068914A1 ARP080104540A ARP080104540A AR068914A1 AR 068914 A1 AR068914 A1 AR 068914A1 AR P080104540 A ARP080104540 A AR P080104540A AR P080104540 A ARP080104540 A AR P080104540A AR 068914 A1 AR068914 A1 AR 068914A1
- Authority
- AR
- Argentina
- Prior art keywords
- plasminogen activator
- treatment
- stroke
- patient
- activator according
- Prior art date
Links
- 102000001938 Plasminogen Activators Human genes 0.000 title abstract 8
- 108010001014 Plasminogen Activators Proteins 0.000 title abstract 8
- 229940127126 plasminogen activator Drugs 0.000 title abstract 8
- 229940126601 medicinal product Drugs 0.000 title 1
- 208000006011 Stroke Diseases 0.000 abstract 4
- 230000037396 body weight Effects 0.000 abstract 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 abstract 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 abstract 1
- 208000031481 Pathologic Constriction Diseases 0.000 abstract 1
- 241001125847 Tinca Species 0.000 abstract 1
- 208000021328 arterial occlusion Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 208000037804 stenosis Diseases 0.000 abstract 1
- 230000036262 stenosis Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Electrotherapy Devices (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Reivindicacion 1: Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejía en un paciente, caracterizado porque antes del tratamiento dicho paciente es seleccionado por exhibir uno o más de los siguientes criterios en la tinca basal: a) tejido cerebral en riesgo, b) oclusion de arteria cerebral, c) alto grado de estenosis, d) un volumen de falta absoluta de coincidencia de al menos 50 centímetros cubicos. Reivindicacion 6: Uso de un activador de plasminogeno segun cualquiera de las reivindicaciones precedentes caracterizado porque el paciente exhibe una apoplejía de calificacion NIHSS de al menos 8, preferiblemente entre 8 y 24 (inclusive). Reivindicacion 7: Uso de un activador de plasminogeno segun cualquiera de las reivindicaciones precedentes, caracterizado porque la oclusion arterial y/o el tejido que se encuentra en riesgo es evaluado diagnostico individual por imágenes antes del tratamiento. Reivindicacion 11: Uso de un activador de plasminogeno segun cualquiera de las reivindicaciones precedentes, caracterizado porque el activador de plasminogeno es administrado al paciente en una dosis de aproximadamente 90 a 125 microg/kg de peso corporal, en particular aproximadamente 90 o aproximadamente 125 microg/kg de peso corporal. Reivindicacion 17: Uso de un activador de plasminogeno segun cualquiera de las reivindicaciones precedentes, caracterizado porque se realiza más de tres horas después del inicio de la apoplejía. Reivindicacion 18: Uso de un activador de plasminogeno segun cualquiera de las reivindicaciones precedentes, caracterizado porque se realiza dentro de 3 a 9 horas después de la aparicion de síntomas de apoplejía.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07020401A EP2050462A1 (en) | 2007-10-18 | 2007-10-18 | Improved treatment of stroke patients |
| EP07022867 | 2007-11-26 | ||
| EP08017954 | 2008-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068914A1 true AR068914A1 (es) | 2009-12-16 |
Family
ID=40567844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104540A AR068914A1 (es) | 2007-10-18 | 2008-10-17 | Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20100272704A1 (es) |
| EP (1) | EP2211898B1 (es) |
| JP (2) | JP5509085B2 (es) |
| KR (1) | KR20100089077A (es) |
| CN (1) | CN101903039B (es) |
| AR (1) | AR068914A1 (es) |
| AU (1) | AU2008314048B2 (es) |
| BR (1) | BRPI0817785A2 (es) |
| CA (1) | CA2702378A1 (es) |
| CL (1) | CL2009000752A1 (es) |
| CY (1) | CY1118417T1 (es) |
| DK (1) | DK2211898T3 (es) |
| EA (1) | EA020776B1 (es) |
| ES (1) | ES2611155T3 (es) |
| HK (1) | HK1151233A1 (es) |
| HR (1) | HRP20170001T1 (es) |
| HU (1) | HUE032867T2 (es) |
| IL (1) | IL205175A0 (es) |
| LT (1) | LT2211898T (es) |
| MX (1) | MX2010004157A (es) |
| MY (1) | MY159200A (es) |
| NZ (1) | NZ584640A (es) |
| PL (1) | PL2211898T3 (es) |
| PT (1) | PT2211898T (es) |
| RS (1) | RS55590B1 (es) |
| SI (1) | SI2211898T1 (es) |
| TW (1) | TWI482628B (es) |
| WO (1) | WO2009049914A2 (es) |
| ZA (1) | ZA201002548B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10153601A1 (de) * | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766075A (en) * | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US5244806A (en) * | 1985-08-26 | 1993-09-14 | Eli Lilly And Company | DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells |
| IL87276A (en) * | 1987-08-03 | 1995-07-31 | Fujisawa Pharmaceutical Co | Analog of a tissue plasminogen activator containing the Pringle 2 and protease regions only, DNA encoding it, processes for its preparation, and pharmaceutical preparations containing it |
| US5094953A (en) * | 1988-03-21 | 1992-03-10 | Genentech, Inc. | Human tissue plasminogen activator variants |
| IE69054B1 (en) * | 1988-07-20 | 1996-08-07 | Schering Ag | Vampire bat salivary plasminogen activators |
| US5714145A (en) * | 1988-09-02 | 1998-02-03 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties |
| DE3903581A1 (de) * | 1989-02-07 | 1990-08-16 | Boehringer Mannheim Gmbh | Gewebs-plasminogenaktivator-derivat |
| US5676947A (en) * | 1989-02-07 | 1997-10-14 | Boehringer Manneheim Gmbh | Method for treating thromboembolic conditions using thrombolytically active proteins |
| US6008019A (en) * | 1989-02-13 | 1999-12-28 | Schering Aktiengesellschaft | Plasminogen activator from saliva of the vampire bat |
| US5891664A (en) * | 1989-04-07 | 1999-04-06 | Cancerforskningsfondet Af 1989 | Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR) |
| US5326700A (en) * | 1990-11-06 | 1994-07-05 | Eli Lilly And Company | DNA sequences encoding t-PA derivatives with cleavable sites |
| ES2082465T3 (es) * | 1991-04-16 | 1996-03-16 | Boehringer Mannheim Gmbh | Unidad farmaceutica de envasado que contiene activadores de plasminogeno para la administracion multiple de bolos. |
| US5595736A (en) * | 1991-04-22 | 1997-01-21 | Eli Lilly And Company | Compounds and methods for treatment of thromboembolic disorders |
| DK0677107T3 (da) * | 1992-12-04 | 1998-03-16 | Schering Ag | Thrombininhibitor fra protostomispyt |
| US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
| GB9412131D0 (en) * | 1994-06-17 | 1994-08-10 | British Bio Technology | Thrombolytic composition |
| US5827832A (en) * | 1995-03-06 | 1998-10-27 | Interneuron Pharmaceuticals, Inc. | Method of protecting brain tissue from cerebral infarction subsequent to ischemia |
| US5786187A (en) * | 1995-09-21 | 1998-07-28 | The Research Foundation Of State University Of New York | Method for reducing neuronal degeneration associated with seizure |
| US5945432A (en) * | 1995-12-22 | 1999-08-31 | The University Of Vermont And State Agricultural College | Thrombolytic agents and thienopyridine derivatives in acute stroke |
| US20020081294A1 (en) * | 1996-01-23 | 2002-06-27 | Genentech, Inc. | Co-administration of a thrombolytic and an anti-CD18 antibody in stroke |
| US5731186A (en) * | 1996-02-05 | 1998-03-24 | Schering Aktiengesellschaft | Method for the production of rDSPA α1 |
| US6354999B1 (en) * | 2000-01-14 | 2002-03-12 | Florence Medical Ltd. | System and method for detecting, localizing, and characterizing occlusions and aneurysms in a vessel |
| GB0025473D0 (en) * | 2000-10-17 | 2000-11-29 | Pfizer Ltd | Pharmaceutical combinations |
| DE10153601A1 (de) * | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
| US20080057050A1 (en) * | 2003-05-02 | 2008-03-06 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
| US20060135425A1 (en) * | 2003-05-02 | 2006-06-22 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
| US20080213244A1 (en) * | 2003-05-05 | 2008-09-04 | Wolfgang Sohngen | Glutamate Receptor Antagonists as Neuroprotectives |
| US20050085478A1 (en) * | 2003-08-22 | 2005-04-21 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage |
| CA2619406A1 (en) * | 2005-08-25 | 2007-03-01 | Biogen Idec Ma Inc. | Nogo receptor polypeptides and polypeptide fragments and uses thereof |
-
2008
- 2008-10-17 TW TW097139886A patent/TWI482628B/zh not_active IP Right Cessation
- 2008-10-17 AR ARP080104540A patent/AR068914A1/es unknown
- 2008-10-20 WO PCT/EP2008/008871 patent/WO2009049914A2/en active Application Filing
- 2008-10-20 BR BRPI0817785-6A patent/BRPI0817785A2/pt not_active IP Right Cessation
- 2008-10-20 MY MYPI2010001704A patent/MY159200A/en unknown
- 2008-10-20 EA EA201070485A patent/EA020776B1/ru not_active IP Right Cessation
- 2008-10-20 US US12/682,779 patent/US20100272704A1/en not_active Abandoned
- 2008-10-20 RS RS20170031A patent/RS55590B1/sr unknown
- 2008-10-20 JP JP2010529300A patent/JP5509085B2/ja not_active Expired - Fee Related
- 2008-10-20 CA CA2702378A patent/CA2702378A1/en not_active Abandoned
- 2008-10-20 AU AU2008314048A patent/AU2008314048B2/en not_active Ceased
- 2008-10-20 PT PT88388970T patent/PT2211898T/pt unknown
- 2008-10-20 CN CN200880112073.2A patent/CN101903039B/zh not_active Expired - Fee Related
- 2008-10-20 MX MX2010004157A patent/MX2010004157A/es active IP Right Grant
- 2008-10-20 NZ NZ584640A patent/NZ584640A/xx not_active IP Right Cessation
- 2008-10-20 KR KR1020107010609A patent/KR20100089077A/ko active Search and Examination
- 2008-10-20 EP EP08838897.0A patent/EP2211898B1/en active Active
- 2008-10-20 SI SI200831750A patent/SI2211898T1/sl unknown
- 2008-10-20 DK DK08838897.0T patent/DK2211898T3/en active
- 2008-10-20 HU HUE08838897A patent/HUE032867T2/en unknown
- 2008-10-20 PL PL08838897T patent/PL2211898T3/pl unknown
- 2008-10-20 LT LTEP08838897.0T patent/LT2211898T/lt unknown
- 2008-10-20 ES ES08838897.0T patent/ES2611155T3/es active Active
-
2009
- 2009-03-27 CL CL2009000752A patent/CL2009000752A1/es unknown
-
2010
- 2010-04-12 ZA ZA2010/02548A patent/ZA201002548B/en unknown
- 2010-04-18 IL IL205175A patent/IL205175A0/en unknown
-
2011
- 2011-05-30 HK HK11105336.9A patent/HK1151233A1/xx not_active IP Right Cessation
-
2014
- 2014-01-07 JP JP2014000825A patent/JP2014065739A/ja not_active Withdrawn
- 2014-02-14 US US14/181,153 patent/US20140314736A1/en not_active Abandoned
-
2017
- 2017-01-03 HR HRP20170001TT patent/HRP20170001T1/hr unknown
- 2017-01-11 CY CY20171100041T patent/CY1118417T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2526648T3 (es) | Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno | |
| AR077484A1 (es) | Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion | |
| AR062522A1 (es) | Tratamiento de desordenes en cartilagos | |
| ATE553772T1 (de) | Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel | |
| PE20170302A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| UY30321A1 (es) | Procedimiento para preparar medicamentos caracterizado por el uso de derivados sustituidos de la 3-metil-7-(2-butin-1-il) xantina y aplicaciones | |
| PE20180203A1 (es) | Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico | |
| WO2009046863A3 (en) | Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent | |
| ATE522225T1 (de) | Verwendung des peptids phpfhlfvy (renin- inhibitor) in anti-angiogenischer therapie von gewissen erkrankungen | |
| WO2009057165A8 (en) | Use of microvesicles (mvs) derived from stem cells for preparing a medicament for endo/epithelial regeneration of damaged or injured tissues or organs, and related in vitro and in vivo methods | |
| WO2009040069A3 (en) | Use of bq-610 alone or in combination with helodermin as a therapeutic agent | |
| WO2009033717A3 (en) | Use of gonadorelin as a therapeutic agent | |
| PE20140872A1 (es) | Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple | |
| CR9181A (es) | Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa | |
| AR110301A1 (es) | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| WO2009033803A3 (en) | Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents | |
| WO2009039991A3 (en) | Use of aviptadil as a therapeutic agent | |
| AR104068A1 (es) | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| WO2009040085A3 (en) | Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) | |
| AR072951A1 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
| ECSP077843A (es) | Tratamiento o prevención del prurito | |
| PE20240657A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicos | |
| AR068914A1 (es) | Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |